Detection of “Candidatus Rickettsia wissemanii” in ticks parasitizing bats (Mammalia: Chiroptera) in the northern Brazilian Amazon

A total of 482 bats representing 32 species and two families were captured in the Amazon forests of the Amapá state in northern Brazil. Nineteen Artibeus planirostris bats (3.9 %) were infested with 160 ticks, all identified as Ornithodoros hasei. Three pools of larvae were screened for rickettsial DNA via polymerase chain reaction (PCR) targeting three rickettsial genes: gltA, ompA and htrA. Only one of them yielded an amplicons of the expected size for all three molecular assays. Comparisons of the obtained sequences including a phylogenetic analysis confirmed the occurrence of “Candidatus Rickettsia wissemanii” in Brazil.

     

The effects of parenteral nutrition on food intake and gastric motility

Frequently, patients receiving parenteral nutrition (PN) report hunger during the parenteral infusion, yet experience early satiety once PN is tapered off. Post-PN satiety can interfere with the ability to consume enough nutrients to maintain body weight and nutritional status. Factors such as caloric quantity of infusate, gastric motility changes, and disease pathology have been related to appetite changes. To investigate the effects of PN on food intake and gastric motility without the complicated interactions associated with disease pathology, four normal, healthy rhesus monkeys (Macaca mulatta) were studied. The monkeys were administered PN in amounts ranging from 25% to 100% of their normal daily caloric intake. Food and water were continuously available. PN consistently suppressed voluntary food intake in direct relationship to the amount of nutrient infused. The frequency of large-amplitude hunger-type gastric contractions decreased from control conditions. Upon cessation of PN, appetite remained suppressed for one to two weeks, indicating a self-limiting physiological basis to post-PN satiety. Thus, reduced appetite following PN termination might occur in the clinical setting and the patients' feelings of satiety may not be completely attributed to lack of cooperation or disease pathology.     

Effects of of habitats and pesticides on aerobic capacity and survival of soil fauna

Faunal health is largely dependent on their soil environment and available litter quality. So the effects of different soil habitats and pesticides on citrate synthase (CS) activity of soil fauna and its population were studied. Methods The soil animals were collected from different pedoecosystems for habitat study. Whereas Vigna radiata based system was selected for pesticidal observations. The field was divided into five equal plots for control and treatment of γ-BHC, quinalphos, carbaryl and cypermethrin. Soil fauna was collected by quadrat method and extracted by Tullgren funnel. Individuals of a species having similar sizes were collected for the estimation of CS activity. They were homogenized and fractions were obtained by differential centrifugation. The activity of CS was assayed spectrophotometrically. Results Citrate synthase (CS) activity of beetle (Rasphytus fregi), woodlouse (PorceUio laevis) and centipede (Scolopendra morsitans) varied significantly with respect to changes in different soil habitats. Though the CS activity of R. fregi, P. laevis, and S. morsitans differed among themselves but the highest activity of CS in these animals was in V. radiata and lowest in A. nilotica based pedoecosystem. The aerobic capacity of centipede was maximum followed by woodlouse and beetle. The treatment of γ-BHC, quinalphos, carbaryl and cypermethrin significantly reduced the CS activity of these animals. γ-BHC showed maximum reduction in CS activity indicating highly toxic effect of organochlorine on aerobic metabolism of soil fauna. However, minimum reduction was obseryed in response to carbaryl (in beetle) or cypermethrin (in woodlouse/centipede) leading to impairment of aerobic capacity. The differences in pesticide effects might be assigned to the differences in chemical nature of pesticides and their interactions with below-ground fauna. Treatment ofγ-BHC and quinalphos reduced the population of Acari, Coleoptera, Collembola, other arthropods as well as total soil fauna. Acari was least affected by γ-BHC and maximally affected (72%) in response to quinalphos. The effect of γ-BHC was fairly similar on Coleoptera, Collembola, other arthropod and total soil fauna suggesting almost similar sensitivity to this pesticide. Likewise, quinalphos was similarly effective on Collemobola and other soil arthropods. Application of carbaryl decreased Acari and Coleoptera population but increased Collembola, other arthropods and total faunal populations. However, application of cypermethrin significantly reduced the population of Acari, Coleoptera, Collembola and total soil fauna and increased the population of other soil arthropods. In both the cases, acarine population was least affected. Conclusion The observations show the habitat-specific variation in aerobic capacity of soil fauna. However, pesticide-dependent loss in population might be due to impairment of aerobic capacity of soil inhabiting animals in desert.     

Evaluation of the impact of pharmacist-led medication reconciliation intervention: a single centre pre–post study from Ethiopia

International Journal of Clinical Pharmacy - Background The role of pharmacists in medication reconciliation (MedRec) is highly acknowledged in many developed nations. However, the impact of this...     

Can we identify older people most vulnerable to living in cold homes during winter?

Purpose

Living in a cold home increases the risk of dying in winter, especially in older people. However, it is unclear which individual factors predict whether older people are living in cold homes.

Use of a case-mix approach to study the trends in the incidence of second primary cancers

Purpose

To analyze trends in second primary cancer (SPC) incidence by using a case-mix approach to standardize on first cancer site distribution.

Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers

We find ourselves in an era of unprecedented growth in the development and use of so-called “orphan” drugs to treat rare diseases, which are poised to represent more than one-fifth of pharmaceutical expenditures by 2022. This widespread use has been facilitated by legislative and regulatory incentives in both the United States and abroad, yet US payers and health systems have not yet made a concerted effort to understand whether and how rare diseases require special considerations on their part and how to adapt traditional methods of health technology assessment and economic evaluation to accommodate these situations. In this article, we explore the general ethical dilemmas that rare diseases present, steps taken by health technology assessment bodies worldwide to define the level of rarity that would necessitate special measures and the modifications to their assessment and valuation processes needed, and the contextual components for rare-disease evaluation that lie outside of the assessment framework as a guide to US decision makers on constructing a formal and relevant process stateside.